EMT is associated with, but does not drive resistance to ALK inhibitors among EML4‐ALK non‐small cell lung cancer

Por Gower, Arjan, Hsu, Wei-Hsun, Hsu, Shuo-Tse, Wang, Yisong, Giaccone, Giuseppe
Publicado no Mol Oncol (2015)

Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations

Por Rao, Guanhua, Pierobon, Mariaelena, Kim, In-Kyu, Hsu, Wei-Hsun, Deng, Jianghong, Moon, Yong-Wha, Petricoin, Emanuel F., Zhang, Yu-Wen, Wang, Yisong, Giaccone, Giuseppe
Publicado no Sci Rep (2017)

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

Por Fox, Lucy C., Cummins, Katherine D., Costello, Ben, Yeung, David, Cleary, Rebecca, Forsyth, Cecily, Tatarczuch, Maciek, Burbury, Kate, Motorna, Olga, Shortt, Jake, Fleming, Shaun, McQuillan, Andrew, Schwarer, Anthony, Harrup, Rosemary, Holmes, Amy, Ratnasingam, Sumita, Chan, Kah-Lok, Hsu, Wei-Hsun, Ashraf, Asma, Putt, Faye, Grigg, Andrew
Publicado no Blood Adv (2017)

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan

Por Lin, Shu-Yung, Yang, Ching-Yao, Liao, Bin-Chi, Ho, Chao-Chi, Liao, Wei-Yu, Chen, Kuan-Yu, Tsai, Tzu-Hsiu, Hsu, Chia-Lin, Hsu, Wei-Hsun, Su, Kang-Yi, Chang, Yih-Leong, Lee, Jih-Hsiang, Lin, Chia-Chi, Shih, Jin-Yuan, Yang, James Chih-Hsin, Yu, Chong-Jen
Publicado no J Cancer (2018)

The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia

Por Minson, Adrian G., Cummins, Katherine, Fox, Lucy, Costello, Ben, Yeung, David, Cleary, Rebecca, Forsyth, Cecily, Tatarczuch, Maciek, Burbury, Kate, Motorna, Olga, Shortt, Jake, Fleming, Shaun, McQuillan, Andrew, Schwarer, Anthony, Harrup, Rosemary, Holmes, Amy, Ratnasingam, Sumita, Chan, Kah-Lok, Hsu, Wei-Hsun, Ashraf, Asma, Putt, Faye, Grigg, Andrew
Publicado no Blood Adv (2019)